Home  /   Products  /   Circulatory system  /   Meglumine sodium succinate (Reamberin) infusions 1.5% 500 ml – [5 vials]

Meglumine sodium succinate (Reamberin) infusions 1.5% 500 ml – [5 vials]

$45.54

A drug with a detoxifying effect for parenteral use. Solutions affecting the water-electrolyte balance

SKU: 62622 Category:

Description

Reamberine Pharmacodynamics
REAMBERIN® has an antihypoxic and antioxidant effect, positively
effect on aerobic processes in cells, reducing the production of free radicals and restoring the energy potential of cells.
The product activates the enzymatic processes of the Krebs cycle and promotes the utilization of fatty acids
and glucose in cells, normalizes acid-base balance and blood gas composition. It has a moderate diuretic effect.

 

Indications
REAMBERIN® is used in adults and children over 1 year old as an antihypoxic and detoxifying agent in acute endogenous and exogenous intoxications of various etiologies.

 

Contraindications .
Individual intolerance, state after craniocerebral trauma accompanied by cerebral edema, acute renal insufficiency, chronic renal disease (stage 5, glomerular filtration rate less than 15 ml/min), pregnancy, breast-feeding period.
Caution
In alkalosis, renal failure.
Administration during pregnancy
and during breastfeeding.
REAMBERIN® is contraindicated in pregnant women and during breast feeding period because of lack of clinical trials in these groups of patients.

 

Dosage and administration

 

  • Adults: administered intravenously by drop infusion at a rate of 1-4.5 ml/min (up to 90 drops per minute). Average daily dose is 10 ml/kg. The course of therapy is up to 11 days.
  • Children: administered intravenously by drip at a rate of 6-10 ml/kg per day at a rate of 3-4 ml/min.
  • The course of therapy is up to 11 days.
  • Administration in elderly patients
  • Studies have not been carried out in elderly patients. Therefore, the drug should be started with a slower speed of administration: 30-40 drops (1-2 ml) a minute.
  • Administration in patients with renal insufficiency
  • Studies have not been carried out in patients with renal failure. Therefore, caution is recommended when using in such patients.
  • Administration in alkalosis
  • In case of decompensated alkalosis, discontinue drug administration until normalization of the acid-base state of blood.